Pharmaceutical giant Gilead Sciences Inc. and generic drugs manufacturer Cipla have collectively informed a California federal judge that they have reached a consensus to settle a proposed class action. The lawsuit in question was filed by a public employees’ health insurance fund who accused the two companies of hatching an anti-competitive patent deal designed to delay the launch of a generic version of the HIV drug Truvada.
This proposed settlement puts an end to the escalating legal dispute that has been critically highlighted within the pharmaceutical industry and healthcare providers’ circles. For more details on the terms of the settlement and its implications, consider referring to the original article that reported on the matter.